Side-by-side guide
Mounjaro vs Zepbound: the full guide
An honest, clinically-framed comparison of Mounjaro and Zepbound — what they do, how they differ, what the evidence shows, and who each tends to suit.
Quick comparison at a glance
The short version — here is how Mounjaro and Zepbound stack up on the questions most patients ask before picking one.
Mounjaro
- Drug class: Dual GLP-1/GIP receptor agonist
- Brand names: Mounjaro (tirzepatide 2.5-15 mg)
- Mechanism: Same as Zepbound — tirzepatide acts on both GLP-1 and GIP receptors to regulate blood sugar, insulin response, and appetite.
- Dosing: Once-weekly subcutaneous injection. Doses from 2.5 mg to 15 mg, titrated over about 20-24 weeks.
- Half-life: Approximately 5 days.
- FDA indication: Adults with type 2 diabetes to improve glycemic control, as an adjunct to diet and exercise.
- FDA status: FDA-approved in 2022 for type 2 diabetes. Not FDA-approved as Mounjaro for weight management (Zepbound is the weight-management brand).
- Manufacturer: Eli Lilly
- Common side effects: Nausea, vomiting, diarrhea, constipation, decreased appetite — standard tirzepatide profile.
- Typical price range: Brand price roughly $1,000-1,200/month without insurance. Typically covered for type 2 diabetes with prior authorization.
Zepbound
- Drug class: Dual GLP-1/GIP receptor agonist
- Brand names: Zepbound (tirzepatide 2.5-15 mg)
- Mechanism: Same as Mounjaro — tirzepatide dual GLP-1/GIP agonist.
- Dosing: Once-weekly subcutaneous injection. Doses from 2.5 mg to 15 mg, identical to Mounjaro's range.
- Half-life: Approximately 5 days.
- FDA indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.
- FDA status: FDA-approved in 2023 based on the SURMOUNT-1 trial.
- Manufacturer: Eli Lilly
- Common side effects: Same as Mounjaro since it's the same active ingredient.
- Typical price range: Roughly $1,100-1,400/month brand price. Coverage for weight management varies by plan.
Yes, Mounjaro and Zepbound are the same tirzepatide
Mounjaro and Zepbound both contain tirzepatide, manufactured by Eli Lilly. Same molecule, same dosing range (2.5 mg to 15 mg), same once-weekly injection. If you compare the pharmacology, they are identical.
Eli Lilly split the brand identities to match the two FDA-approved indications — diabetes (Mounjaro) and weight management (Zepbound) — because the regulatory, insurance, and marketing pathways for those two indications are different enough to warrant it. This is the same pattern Novo Nordisk used for semaglutide with Ozempic (diabetes) and Wegovy (weight management).
Why two brands for the same drug?
Several reasons, all practical:
- Separate FDA approvals. A drug maker must submit separate FDA applications for each indication. Diabetes and chronic weight management are regulated as separate indications with separate safety and efficacy endpoints. Eli Lilly filed two NDAs for tirzepatide.
- Different patient populations and marketing. Diabetes and obesity are distinct clinical audiences. A separate brand lets the manufacturer market to each population differently without muddying the message.
- Insurance coverage differences. Diabetes medications have long-established insurance coverage pathways. Weight management medications are newer on most formularies and are treated differently by payers. A separate brand identity makes it easier to handle the two coverage worlds.
- Supply allocation. When manufacturing capacity is constrained, Eli Lilly can decide how to allocate supply between Mounjaro (diabetes) and Zepbound (weight management) based on demand and priority. This happened during multiple shortage periods.
Mounjaro off-label for weight loss: the honest picture
When Zepbound was unavailable or insurance declined it for weight management, some physicians prescribed Mounjaro off-label for non-diabetic weight-management patients — the same pattern as off-label Ozempic. This was legal, but it raised insurance coverage issues (insurance typically declines Mounjaro for patients without documented type 2 diabetes) and documentation complications.
Today, with Zepbound more widely available, the appropriate FDA-approved choice for a patient whose primary goal is weight management is Zepbound, not off-label Mounjaro. A physician makes the call based on your clinical picture, insurance, and current brand availability.
Who tends to do better on each
There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.
Mounjaro
Mounjaro is the right choice for adults with type 2 diabetes who are candidates for tirzepatide to manage blood sugar. It is not FDA-approved for weight management in patients without diabetes, and off-label use for that purpose raises the same coverage and documentation issues as off-label Ozempic.
Zepbound
Zepbound is the right choice for adults with obesity or overweight plus a weight-related condition whose primary goal is weight management. It is the FDA-approved option for that indication and is the appropriate prescription when the clinical target is weight loss rather than diabetes control.
A prescription is not guaranteed. Your Puri-affiliated provider may decline to prescribe either medication if the clinical picture does not support it, if you have a contraindication, or if a different treatment is more appropriate for your situation. You will not be charged for medication you do not receive.
